-
1 Comment
From a valuation standpoint, the stock is 188.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3865.7.
Based on the above factors, Bolt Biotherapeutics, Inc. Common Stock gets an overall score of 0/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US0977021049 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.96 |
|---|---|
| Target Price | 1.125 |
| PE Ratio | None |
| Market Cap | 14M |
| Dividend Yield | None |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BOLT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
